• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The object of this patent of invention is a pharmaceutical composition for the treatment of skin lesions containing a combination of 4 active substances, namely diclofenac sodium, clotrimazole, sulfanilamide and benzyl alcohol, all of them in a topical administration formulation in the skin, of semi-solid consistency in a structure of hydrophilic gel, with a viscous and translucent texture, easily applicable on the skin and capable of being applied uniformly. The formulation contains 1 gram (1,000 mg.) diclofenac sodium in a proportion of 10 mg. And 60 mg; clotrimazole in a proportion of between 10 mg. And 60 mg; sulfanilamide in a ratio of 50 mg. And 150 mg. And benzyl alcohol in a proportion of between 10 mg. And 80 mg., contained in the same formulation. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2562985A1
    申请号:ES201531954
    申请日:2015-12-31
    公开日:2016-03-09
    发明作者:Enrique Blanxart Sena
    申请人:Enrique Blanxart Sena；
    IPC主号:
    专利说明:

    5
    10
    fifteen
    twenty
    25
    30
    35
    DESCRIPTION
    The present invention relates to a pharmaceutical composition for the treatment of skin lesions.
    Background of the invention
    The skin, considered the largest organ of the human body, is also possibly one of the ones that suffers the most wear, continually renewing itself with the formation of new cells that replace dead cells and prone to suffer injuries. In reality, the skin acts as an effective defense that covers the entire organism, isolating it from everything that surrounds it and specifically from any external aggression. Structurally, the skin is not uniform throughout the body, its thickness varies depending on the needs of protection and its relationship with the environment, being thicker where there is greater contact and / or rubbing and therefore requires greater resistance, for example the feet and in particular the heels, and being thinner in other areas, such as the eyelids or the face, the skin structure comprising three parts or layers: epidermis, dermis and hypodermis, the epidermis being the most superficial and the hypodermis or subcutaneous tissue, the deepest.
    Logically, being the skin the protective organ that covers the entire human body is continually exposed to multiple injuries, due to accidental circumstances such as bumps, friction, burns, etc. and also effects that may be consequences of other diseases such as ulcers derived from diabetes, vascular diseases or infections. In any case, an aggression in the skin that alters its structure should be considered as an injury that requires adequate medical treatment since any lesion of the skin or mucous membrane with loss of substance, that is, an ulcer, involves Considerable infection risks likely to affect other internal organs and / or not to heal and become chronic.
    In addition to ulcerations, the skin is susceptible to multiple alterations in its structure, such as keratosis caused by sun exposure, epidermal tumors, acne, psoriasis, warts or pustules.
    Any skin lesion requires medical treatment to relieve and treat its symptoms and recover its structure. There are surgical treatments,
    2
    5
    10
    fifteen
    twenty
    25
    30
    35
    suitable for particularly significant skin pathologies such as tumors or burns that require direct intervention to clean and treat the affected area, but most procedures are non-surgical with a treatment of less aggressiveness based on the utilization of ointments, ointments, gels or the like of direct application on the skin to relieve and treat the symptoms that may occur.
    One of the most dispensed pharmaceutical compositions is the combination of neomycin, polymyxin and bacitracin, especially suitable for burns, scrapes or cuts that result in an infection, being highly effective because of its content in antibiotics that work to stop the growth of bacteria. Also, diclofenac topic, of the non-steroidal anti-inflammatory type, is of effective use to treat actmic keratosis and osteoarthritis but is scarcely effective, in itself, in other types of skin lesions as they do not have antibacterial properties.
    At the industrial property level there are many pharmaceutical patents that have formulations and compositions intended for the treatment of skin conditions such as for example US2010221245 for the treatment of acne and containing an antibacterial agent, for example, bacitracin, an anti-inflammatory agent, for example, benzoyl peroxide and an antioxidant agent, for example, omeprazole and sodium pantoprazole. For its part, WO2009158687 develops a formulation that covers a wide range of skin effects, such as psoriasis, skin infection, actic keratosis, eczematous dermatitis, Raynaud's phenomenon symptoms, lupus erythematosus smtoma and skin cancer, which includes active anti-seborrheic, dermatological, antipsoriasic, keratolrtic and vasotropic principles.
    As for alternative treatments, it is advisable to apply on the skin, either in gel or cream format or by compresses in case of open lesions, certain combinations of herbs, vitamins and amino acids, corticosteroid creams, oral antihistammics (allergy) in sporadic circumstances , lotions and moisturizers etc. Among these natural remedies, cite Aloe Vera in gel format especially effective for pressure ulcers; the combination of curcuma root and Hazel, Agrimony (Agrimonia eupatoria) also popularly known as St. William's Wort, hypericum (Hypericum perforatum), Yarrow (Achillea millefolium) or aquilea or the combination of sugar and honey.
    5
    10
    fifteen
    twenty
    25
    30
    35
    Object of the invention
    The present invention relates to a pharmaceutical composition for the treatment of skin lesions that occurs mainly in gel, ointment or ointment format.
    In particular, the composition claimed is specially formulated to act against keratosis caused by sun exposure, wide-spectrum epidermal tumors, acne, warts and pustules, being equally effective in relieving ulcers and open skin wounds since it acts to inhibit the division and proliferation of fungi and microorganisms, reducing inflammation, sclerosis and hardening of the ulcer, leaving, after a continuous and correctly dosed application, a crust that by its desiccation is released from the skin and falls on its own alone.
    In general, it is obvious that any formulation that claims to have an effective result against skin disorders must combine various active ingredients that mainly combine antibacterial and anti-inflammatory properties capable of acting against germs, bacteria, fungi or the like that proliferate especially in open wounds in the skin. skin and analgesic properties that reduce and relieve pain.
    The claimed composition contains a combination of four active substances that meet the needs described, namely Diclofenac sodium, Clotrimazole, Sulfanilamide and Benzyl Alcohol, all of them in a topically administered administration formulation in the skin, of semi-solid consistency in a Hydrophilic gel structure, with a viscous and translucent texture, easily applicable to the skin and capable of being applied uniformly.
    The formulation contains per 1 gram (1,000 mg.) Diclofenac sodium in a proportion of between 10 mg. and 60 mg .; Clotrimazole in a proportion between 10 mg. and 60 mg .; Sulfanilamide in a proportion between 50 mg. and 150 mg. and benzyl alcohol in a proportion of between 10 mg. and 80 mg., contained in the same formulation.
    The four aforementioned active substances have, in particular, different properties that, added together, act in an effective manner against the aforementioned skin lesions.
    Diclofenac sodium is a medicine that belongs to the family of non-steroidal anti-inflammatory drugs (NSAIDs), therefore with properties that act against
    4
    5
    10
    fifteen
    twenty
    25
    30
    35
    inflammation and also of an analgesic nature, to which are added muscle relaxant properties that relieve muscle spasms.
    Clotrimazole is an antomicomic or antifungal medication, that is, capable of acting against certain fungi, preventing their growth or destroying them.
    Sulfanilamide is an antibiotic that belongs to the group of sulfa drugs, effective in superficial infections of the skin of bacterial origin, acting on the wall of the bacteria, eliminating them and thus preventing the infection from spreading.
    Benzyl Alcohol is an antimicrobial preservative with certain disinfectant and anesthetic properties in a local application.
    The sum of these substances reinforces the positive properties of each of them, which translates into a high effectiveness in the processes that involve skin lesions when acting together with antibacterial, anti-inflammatory and analgesic / anesthetic properties.
    The pharmaceutical composition contains at least one of the following excipients: Coconut oil, Isopropyl Alcohol, Paraffin, Propylene Glycol, Carbitol, Stearates and Water in sufficient quantity
    Depending on the percentage of water, the developed pharmaceutical formulation has a cream or ointment structure.
    The preferred dosage is one application on the damaged skin every 24 hours.
    The application guideline is as follows:
    1. Apply a small amount of gel covering the area to be treated.
    2. Cover the area to prevent evaporation and dryness of the gel. Keep covered for 12 hours.
    a) It is usually sufficient to apply a small sheet of soft plastic (polyethylene or similar) or
    10
    b) In case of open wounds or suppurating sores, apply a gauze instead of the plastic sheet.
    3. At 12 hours, discover and wash with water and soap in a tablet, especially neutral.
    4. Keep the area to be treated without covering, drying it in the open air for 12 hours.
    5. At 12 o'clock, start a new application schedule, that is, apply a small amount of gel covering the area to be treated.
    It is not considered necessary to make this description more extensive so that any person skilled in the art understands the scope of the invention and the advantages derived from this composition. The terms in which this report has been written should always be taken in a broad and non-limiting sense.
    权利要求:
    Claims (5)
    [1]
    5
    10
    fifteen
    twenty
    25
    30
    35
    1st Pharmaceutical Composition for the treatment of skin lesions characterized in that it contains a combination of four active substances, Diclofenac sodium, Clotrimazole, Sulfanilamide and Bentilic Alcohol, contained, together with certain excipients, in the same formulation.
    2nd Pharmaceutical composition for the treatment of skin lesions, according to the claim, essentially characterized in that the formulation contains 1 gram (1,000 mg.) Sodium diclofenac in a proportion of between 10 mg. and 60 mg.
    3rd Pharmaceutical composition for the treatment of skin lesions, according to the claim, essentially characterized in that the formulation contains 1 gram (1,000 mg.) Clotrimazole in a proportion of between 10 mg. and 60 mg.
    4th Pharmaceutical composition for the treatment of skin lesions, according to the 1st claim, essentially characterized in that the formulation contains per 1 gram (1,000 mg.) Sulfanilamide in a proportion of between 50 mg. and 150 mg.
    5th Pharmaceutical composition for the treatment of skin lesions, according to the 1st claim, essentially characterized in that the formulation contains per 1 gram (1,000 mg.) Benzyl alcohol in a proportion of between 10 mg. and 80 mg.,
    6a Pharmaceutical composition for the treatment of skin lesions, according to the 1st claim, essentially characterized in that it contains at least one of the following excipients: Coconut oil, Isopropyl Alcohol, Paraffin, Propylene Glycol, Carbitol, Stearates and Water in sufficient quantity.
    7a Pharmaceutical composition for the treatment of skin lesions, according to the preceding claims, characterized essentially in that the formulation is topically administered in the skin, of semi-solid consistency in a hydrophilic gel structure, with a viscous and translucent texture.
    8a Pharmaceutical composition for the treatment of skin lesions, according to the 1st and 7th claims, essentially characterized in that the preferred dosage is an application on the damaged skin every 24 hours.
    7
    9th Pharmaceutical composition for the treatment of skin lesions, according to the 8th claim, essentially characterized in that the application pattern is as follows:
    10
    1. Apply a small amount of gel covering the area to be treated.
    [2]
    2. Cover the area to prevent evaporation and dryness of the gel. Keep covered for 12 hours.
    to. Cover with a small sheet of soft plastic (polyethylene or similar) or
    b. In case of open wounds or suppurating sores, apply gauze.
    [3]
    3. Discover and wash with water and soap in a tablet, especially neutral.
    [4]
    4. Keep the area to be treated without covering, drying it in the open air for 12 hours.
    [5]
    5. At 12 noon, start a new application guideline.
    10th Pharmaceutical composition for the treatment of skin lesions, according to the 1st and 6th claims, characterized essentially because according to the percentage of water, the developed pharmaceutical formulation has a cream or ointment structure.
    11a Pharmaceutical composition for the treatment of skin lesions, according to the preceding claims, essentially characterized in that it acts against keratosis 20 produced by sun exposure, wide-spectrum epidermal tumors, acne, warts and
    Pustules, being equally effective in relieving ulcers and open skin wounds.
    类似技术:
    公开号 | 公开日 | 专利标题
    Alam et al.2014|Honey: a potential therapeutic agent for managing diabetic wounds
    Davis et al.1989|Wound healing. Oral and topical activity of Aloe vera
    ES2846854T3|2021-07-29|Antiseptic compositions comprising silver and menthol ions and uses thereof
    Kumari et al.2010|Topical treatment of Klebsiella pneumoniae B5055 induced burn wound infection in mice using natural products
    JP2011522831A|2011-08-04|Acne treatment composition containing nanosilver and use thereof
    ES2719847T3|2019-07-16|Antiseptic composition
    US20100003311A1|2010-01-07|Antimicrobial Composition
    ES2860578T3|2021-10-05|Composition for use in reducing scab formation and promoting healing.
    Taylor et al.2011|Postprocedural wound-healing efficacy following removal of dermatosis papulosa nigra lesions in an African American population: a comparison of a skin protectant ointment and a topical antibiotic
    US20140142522A1|2014-05-22|Moist dressing with honeycomb pattern and drain channels
    WO2004089406A1|2004-10-21|Topical composition in the form of a gel for treating skin burns
    EP2755670B1|2016-05-11|Compositions for the treatment of peripheral ulcers of various origins
    Drudi et al.2018|Aloe barbadensis miller versus silver sulfadiazine creams for wound healing by secondary intention in dogs and cats: A randomized controlled study
    CN111372601A|2020-07-03|Wound debriding compositions and methods of treating wounds
    WO2016118644A1|2016-07-28|Compositions and methods of treating microbes
    ES2562985B1|2016-09-14|Pharmaceutical composition for the treatment of skin lesions
    WO2016054757A1|2016-04-14|Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, camomile and propolis
    ES2684519T3|2018-10-03|Dermatological composition based on algae and olive leaf extracts
    US9023399B2|2015-05-05|Water-soluble anti-inflammatory cream with natural ingredients base
    Gardner2021|L-Mesitran®
    Kircik2009|Study of trolamine-containing topical emulsion for wound healing after shave biopsy
    US20210244785A1|2021-08-12|Compositions and methods for the antiseptic treatment of biofilms on mammalian tissue
    Mishra et al.2014|Topical antibiotics and semisolid dosage forms
    Paras et al.2020|A Review on Burn and it’s Management Strategies
    ES2568517B1|2017-02-13|Composition for controlled release of compounds
    同族专利:
    公开号 | 公开日
    ES2562985B1|2016-09-14|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2002078648A2|2001-03-30|2002-10-10|Novartis Consumer Health S.A.|Topical composition comprising an antifungal|
    US20050014729A1|2003-07-16|2005-01-20|Pharmacia Corporation|Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith|
    US20050147570A1|2004-01-06|2005-07-07|Nordsiek Michael T.|Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne|
    US20100221245A1|2009-02-27|2010-09-02|Audrey Kunin|Topical skin care composition|
    CN104800148A|2015-04-20|2015-07-29|程伟智|Clotrimazole emulsifiable paste and preparation method thereof|
    法律状态:
    2016-09-14| FG2A| Definitive protection|Ref document number: 2562985 Country of ref document: ES Kind code of ref document: B1 Effective date: 20160914 |
    2021-09-29| FD2A| Announcement of lapse in spain|Effective date: 20210929 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201531954A|ES2562985B1|2015-12-31|2015-12-31|Pharmaceutical composition for the treatment of skin lesions|ES201531954A| ES2562985B1|2015-12-31|2015-12-31|Pharmaceutical composition for the treatment of skin lesions|
    [返回顶部]